Zimmer Biomet Holdings Inc. (NYSE:ZBH) was upgraded by investment analysts at Citigroup Inc. from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday.

Other equities analysts also recently issued research reports about the company. SunTrust Banks Inc. initiated coverage on Zimmer Biomet Holdings in a research report on Thursday, August 11th. They issued a “buy” rating and a $155.00 target price on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $150.00 price target on shares of Zimmer Biomet Holdings in a report on Monday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $130.00 price target (down previously from $150.00) on shares of Zimmer Biomet Holdings in a report on Monday, October 31st. Argus reaffirmed a “buy” rating and issued a $140.00 price target on shares of Zimmer Biomet Holdings in a report on Thursday, September 22nd. Finally, RBC Capital Markets set a $143.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Wednesday, September 14th. Four investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $131.15.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings (NYSE:ZBH) opened at 101.86 on Tuesday. The company’s 50-day moving average price is $111.49 and its 200-day moving average price is $121.53. Zimmer Biomet Holdings has a 12-month low of $88.27 and a 12-month high of $133.21. The stock has a market cap of $20.40 billion, a PE ratio of 57.03 and a beta of 1.28.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, meeting the consensus estimate of $1.79. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings will post $7.92 EPS for the current fiscal year.

WARNING: “Citigroup Inc. Upgrades Zimmer Biomet Holdings Inc. (ZBH) to “Neutral”” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/12/01/citigroup-inc-upgrades-zimmer-biomet-holdings-inc-zbh-to-neutral.html.

In related news, insider Daniel E. Williamson sold 2,716 shares of Zimmer Biomet Holdings stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $129.96, for a total value of $352,971.36. Following the completion of the transaction, the insider now directly owns 2,000 shares in the company, valued at $259,920. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.22% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Liberty Capital Management Inc. acquired a new stake in shares of Zimmer Biomet Holdings during the third quarter worth about $108,000. NEXT Financial Group Inc increased its stake in shares of Zimmer Biomet Holdings by 64.5% in the third quarter. NEXT Financial Group Inc now owns 913 shares of the company’s stock worth $119,000 after buying an additional 358 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Zimmer Biomet Holdings by 205.3% in the second quarter. Tower Research Capital LLC TRC now owns 916 shares of the company’s stock worth $110,000 after buying an additional 616 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Zimmer Biomet Holdings by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 964 shares of the company’s stock worth $125,000 after buying an additional 5 shares during the period. Finally, Acrospire Investment Management LLC acquired a new stake in shares of Zimmer Biomet Holdings during the third quarter worth about $130,000. Hedge funds and other institutional investors own 85.05% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.